Stockscreener 앱 받기
490.83
2.55%
-12.86
시간 외 거래:
490.83
전일 마감가:
$503.69
열려 있는:
$503.88
하루 거래량:
342.53K
Relative Volume:
0.70
시가총액:
$21.13B
수익:
$3.08B
순이익/손실:
$1.24B
주가수익비율:
19.16
EPS:
25.6108
순현금흐름:
$1.07B
1주 성능:
+0.73%
1개월 성능:
+2.36%
6개월 성능:
+66.71%
1년 성능:
+33.88%
1일 변동 폭
$486.33
$504.59
1주일 범위
$479.59
$512.74
52주 변동 폭
$266.98
$519.99
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - ulpravda.ru
Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - ulpravda.ru
MannKind Provides Business Updates and 2026 Growth Drivers - Benzinga
Director Jan Malcolm Sells Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (UTHR): UBS Raises Price Target, Maintains B - GuruFocus
United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat
United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics Corporation $UTHR Position Increased by Cwm LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView — Track All Markets
Death Cross: Can United Therapeutics Corporation stock sustain market leadershipTrend Reversal & AI Based Buy/Sell Signal Reports - moha.gov.vn
Pacer Advisors Inc. Decreases Position in United Therapeutics Corporation $UTHR - MarketBeat
S&P 500 Futures Flat In Premarket Trading; United Therapeutics, Intel Lag - 富途牛牛
S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag - Barron's
United Therapeutics (NASDAQ:UTHR) Reaches New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics (NASDAQ:UTHR) Nasdaq Index Targeted Biotech - Kalkine Media
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Louis Sullivan Sells 5,950 Shares - MarketBeat
United Therapeutics Director Malcolm Jan Sells Shares - TradingView — Track All Markets
Voya Investment Management LLC Lowers Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Wedge Capital Management L L P NC Reduces Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR): Revisiting Valuation After Xenotransplantation Progress and Strong Financial Performance - simplywall.st
Will United Therapeutics Corporation (UTH) stock see valuation expansionJuly 2025 Earnings & Safe Capital Allocation Plans - Улправда
VIX Spike: Will United Therapeutics Corporation (UTH) stock see valuation expansionQuarterly Investment Review & Growth-Oriented Investment Plans - Улправда
Chmn Rothblatt Files To Sell 2,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 2,000 Shares - MarketBeat
United Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Published on: 2025-12-19 23:14:09 - Улправда
United Therapeutics stock hits all-time high at 514.05 USD - Investing.com
United Therapeutics stock hits all-time high at 514.05 USD By Investing.com - Investing.com Canada
How resilient is United Therapeutics Corporation stock in market downturnsJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда
Why United Therapeutics Corporation stock could see breakout soonJuly 2025 Levels & Daily Chart Pattern Signal Reports - DonanımHaber
Osaic Holdings Inc. Raises Stake in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics Corporation (UTH) stock beat revenue estimatesJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative? - simplywall.st
James Edgemond Sells 3,517 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $495,950.00 in Stock - MarketBeat
UNITED THERAPEUTICS Director Sells 1,000 Shares - TradingView — Track All Markets
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
Dir Patusky Files To Sell 1,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
21.67%
1.12%
자본화:
|
볼륨(24시간):